214 related articles for article (PubMed ID: 28699788)
1. Allogeneic cell therapy manufacturing: process development technologies and facility design options.
Abbasalizadeh S; Pakzad M; Cabral JMS; Baharvand H
Expert Opin Biol Ther; 2017 Oct; 17(10):1201-1219. PubMed ID: 28699788
[TBL] [Abstract][Full Text] [Related]
2. Draft of Iranian National Guideline for Cell Therapy Manufacturing.
Aghayan HR; Arjmand B; Ahmadbeigi N; Gheisari Y; Vasei M
Arch Iran Med; 2017 Aug; 20(8):547-550. PubMed ID: 28846019
[TBL] [Abstract][Full Text] [Related]
3. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
Abbasalizadeh S; Baharvand H
Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
[TBL] [Abstract][Full Text] [Related]
4. The translation of cell-based therapies: clinical landscape and manufacturing challenges.
Heathman TR; Nienow AW; McCall MJ; Coopman K; Kara B; Hewitt CJ
Regen Med; 2015; 10(1):49-64. PubMed ID: 25562352
[TBL] [Abstract][Full Text] [Related]
5. GMP-compliant human adipose tissue-derived mesenchymal stem cells for cellular therapy.
Aghayan HR; Goodarzi P; Arjmand B
Methods Mol Biol; 2015; 1283():93-107. PubMed ID: 25138723
[TBL] [Abstract][Full Text] [Related]
6. Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications.
Wuchter P; Bieback K; Schrezenmeier H; Bornhäuser M; Müller LP; Bönig H; Wagner W; Meisel R; Pavel P; Tonn T; Lang P; Müller I; Renner M; Malcherek G; Saffrich R; Buss EC; Horn P; Rojewski M; Schmitt A; Ho AD; Sanzenbacher R; Schmitt M
Cytotherapy; 2015 Feb; 17(2):128-39. PubMed ID: 24856898
[TBL] [Abstract][Full Text] [Related]
7. GMP-grade human fetal liver-derived mesenchymal stem cells for clinical transplantation.
Larijani B; Aghayan HR; Goodarzi P; Arjmand B
Methods Mol Biol; 2015; 1283():123-36. PubMed ID: 25092054
[TBL] [Abstract][Full Text] [Related]
8. Platforms for Manufacturing Allogeneic, Autologous and iPSC Cell Therapy Products: An Industry Perspective.
Abraham E; Ahmadian BB; Holderness K; Levinson Y; McAfee E
Adv Biochem Eng Biotechnol; 2018; 165():323-350. PubMed ID: 28534167
[TBL] [Abstract][Full Text] [Related]
9. Generation of mesenchymal stem cells as a medicinal product in organ transplantation.
Verbeek R
Curr Opin Organ Transplant; 2013 Feb; 18(1):65-70. PubMed ID: 23222173
[TBL] [Abstract][Full Text] [Related]
10. Standard operating procedure for the good manufacturing practice-compliant production of human bone marrow mesenchymal stem cells.
Roseti L; Serra M; Bassi A
Methods Mol Biol; 2015; 1283():171-86. PubMed ID: 25092055
[TBL] [Abstract][Full Text] [Related]
11. An Innovative, Comprehensive Mapping and Multiscale Analysis of Registered Trials for Stem Cell-Based Regenerative Medicine.
Monsarrat P; Vergnes JN; Planat-Bénard V; Ravaud P; Kémoun P; Sensebé L; Casteilla L
Stem Cells Transl Med; 2016 Jun; 5(6):826-35. PubMed ID: 27075765
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies.
Simaria AS; Hassan S; Varadaraju H; Rowley J; Warren K; Vanek P; Farid SS
Biotechnol Bioeng; 2014 Jan; 111(1):69-83. PubMed ID: 23893544
[TBL] [Abstract][Full Text] [Related]
13. Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy.
Li T; Xia M; Gao Y; Chen Y; Xu Y
Expert Opin Biol Ther; 2015; 15(9):1293-306. PubMed ID: 26067213
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic cell therapy bioprocess economics and optimization: downstream processing decisions.
Hassan S; Simaria AS; Varadaraju H; Gupta S; Warren K; Farid SS
Regen Med; 2015; 10(5):591-609. PubMed ID: 26237703
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic human cells: manufacture for cell therapy/regenerative medicine.
van den Bos C; Keefe R; Schirmaier C; McCaman M
Adv Biochem Eng Biotechnol; 2014; 138():61-97. PubMed ID: 23934363
[TBL] [Abstract][Full Text] [Related]
16. Clinical-scale expansion of mesenchymal stromal cells: a large banking experience.
Lechanteur C; Briquet A; Giet O; Delloye O; Baudoux E; Beguin Y
J Transl Med; 2016 May; 14(1):145. PubMed ID: 27207011
[TBL] [Abstract][Full Text] [Related]
17. Commercial Scale Manufacturing of Allogeneic Cell Therapy.
Pigeau GM; Csaszar E; Dulgar-Tulloch A
Front Med (Lausanne); 2018; 5():233. PubMed ID: 30186836
[TBL] [Abstract][Full Text] [Related]
18. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
Garcia FA; Vandiver MW
PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
[TBL] [Abstract][Full Text] [Related]
19. A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications.
Pakzad M; Hassani SN; Abbasi F; Hajizadeh-Saffar E; Taghiyar L; Fallah N; Haghparast N; Samadian A; Ganjibakhsh M; Dominici M; Baharvand H
Stem Cell Rev Rep; 2022 Oct; 18(7):2279-2295. PubMed ID: 35175538
[TBL] [Abstract][Full Text] [Related]
20. Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow-derived multipotent mesenchymal stromal cells.
Codinach M; Blanco M; Ortega I; Lloret M; Reales L; Coca MI; Torrents S; Doral M; Oliver-Vila I; Requena-Montero M; Vives J; Garcia-López J
Cytotherapy; 2016 Sep; 18(9):1197-208. PubMed ID: 27424149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
